Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050389 | 0.84 | CYP19A1 (0.33) | CYP19A1APPLMNAMEN1MAPT | |
| SCHEMBL9345204 | 0.84 | LMNA (0.52) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL5049012 | 0.83 | CYP19A1 (0.37) | CYP19A1APPCA12CA4CA6 | |
| SCHEMBL5051337 | 0.80 | — | — | |
| SCHEMBL5050204 | 0.73 | IDO1 (0.38) | APPLMNAMEN1KMT2ACA1 | |
| SCHEMBL23455531 | 0.69 | CA12 (0.47) | CYP19A1APPCA12CA4CA6 | |
| SCHEMBL5049001 | 0.69 | CA12 (0.47) | CYP19A1APPCA12CA4CA6 | |
| SCHEMBL5049007 | 0.69 | CYP4F2 (0.49) | CYP19A1APPCA12CA4CA6 | |
| SCHEMBL8397725 | 0.68 | ALDH1A1 (0.45) | CA12CA4CA6CA5ACA7 | |
| SCHEMBL5051344 | 0.67 | CA12 (0.44) | CYP19A1APPCA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | claimed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | claimed |
| EP-4149549-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MacroGenics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | MACROGENICS, INC. (US) | 2023-02-28 | — | — | US | claimed |
| WO-2021231309-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210171641-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2021-06-10 | — | — | US | claimed |
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | MACROGENICS, INC. (US) | 2021-03-30 | — | — | US | claimed |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2019-05-02 | — | — | US | claimed |
| EP-3442574-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MacroGenics, Inc. (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2017180813-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2017-10-19 | — | — | WO | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-4149549-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MacroGenics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2017180813-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | disclosed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | disclosed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | CYP19A1 4582/4885APP 4315/4885CA12 486/4885 |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | CD274, CD2, CD22 | CYP19A1 4582/4885APP 4315/4885CA12 486/4885 |
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | CD274, HRH3, CD2 | CYP19A1 4663/4885APP 4103/4885CA12 415/4885 |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | CYP19A1 4629/4885APP 4245/4885CA12 415/4885 |
| US-20210171641-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | CYP19A1 4629/4885APP 4245/4885CA12 415/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | CYP19A1 303/4885APP 1278/4885CA12 1008/4885 |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | CD274, PDCD1, H1-3 | CYP19A1 3471/4885APP 4709/4885CA12 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.